EconPapers    
Economics at your fingertips  
 

Targeting the conserved active site of splicing machines with specific and selective small molecule modulators

Ilaria Silvestri, Jacopo Manigrasso, Alessandro Andreani, Nicoletta Brindani, Caroline Mas, Jean-Baptiste Reiser, Pietro Vidossich, Gianfranco Martino, Andrew A. McCarthy, Marco Vivo () and Marco Marcia ()
Additional contact information
Ilaria Silvestri: Istituto Italiano di Tecnologia
Jacopo Manigrasso: Istituto Italiano di Tecnologia
Alessandro Andreani: Istituto Italiano di Tecnologia
Nicoletta Brindani: Istituto Italiano di Tecnologia
Caroline Mas: ISBG
Jean-Baptiste Reiser: IBS
Pietro Vidossich: Istituto Italiano di Tecnologia
Gianfranco Martino: Istituto Italiano di Tecnologia
Andrew A. McCarthy: European Molecular Biology Laboratory (EMBL) Grenoble
Marco Vivo: Istituto Italiano di Tecnologia
Marco Marcia: European Molecular Biology Laboratory (EMBL) Grenoble

Nature Communications, 2024, vol. 15, issue 1, 1-15

Abstract: Abstract The self-splicing group II introns are bacterial and organellar ancestors of the nuclear spliceosome and retro-transposable elements of pharmacological and biotechnological importance. Integrating enzymatic, crystallographic, and simulation studies, we demonstrate how these introns recognize small molecules through their conserved active site. These RNA-binding small molecules selectively inhibit the two steps of splicing by adopting distinctive poses at different stages of catalysis, and by preventing crucial active site conformational changes that are essential for splicing progression. Our data exemplify the enormous power of RNA binders to mechanistically probe vital cellular pathways. Most importantly, by proving that the evolutionarily-conserved RNA core of splicing machines can recognize small molecules specifically, our work provides a solid basis for the rational design of splicing modulators not only against bacterial and organellar introns, but also against the human spliceosome, which is a validated drug target for the treatment of congenital diseases and cancers.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-48697-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48697-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-48697-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48697-0